The global PCR-based infectious diseases market is expected to reach USD 7,720,895.13 thousand by 2031 from USD 4,737,570.00 thousand in 2023, growing with a CAGR of 6.6% in the forecast period of 2024 to 2031.
Market Segmentation
Global PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global PCR-based Infectious Diseases Market Dynamics
- Driver
- Increasing PCR-based research activities
- Restraint
- High cost of PCR test services
- Opportunity
- Disease surveillance for early detection and monitoring of infectious diseases
Market Players
Some of the major market players operating in the global PCR-based infectious diseases market are:
- DNA Labs India
- DrSafeHands
- Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
- Max Lab
- MicroGen Diagnostics
- pathlab
- The Washington Travel Clinic
- Clarewell Clinics
- AZOVA
- One Life Home Health Care Center
- LalpathLabs
TABLE OF CONTENTS
1 INTRODUCTION 45
- 1.1 OBJECTIVES OF THE STUDY 45
- 1.2 MARKET DEFINITION 45
- 1.3 OVERVIEW OF GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET 45
- 1.4 CURRENCY AND PRICING 46
- 1.5 LIMITATIONS 47
- 1.6 MARKETS COVERED 47
2 MARKET SEGMENTATION 50
- 2.1 MARKETS COVERED 50
- 2.2 GEOGRAPHICAL SCOPE 51
- 2.3 YEARS CONSIDERED FOR THE STUDY 52
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 53
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
- 2.6 MULTIVARIATE MODELLING 57
- 2.7 MARKET APPLICATION COVERAGE GRID 58
- 2.8 TEST TYPE LIFELINE CURVE 59
- 2.9 DBMR MARKET POSITION GRID 60
- 2.10 VENDOR SHARE ANALYSIS 61
- 2.11 SECONDARY SOURCES 62
- 2.12 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 66
- 4.1 PESTEL ANALYSIS 69
- 4.2 PORTER'S FIVE FORCES 70
5 MARKET OVERVIEW 71
- 5.1 DRIVERS 73
- 5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 73
- 5.1.2 RISING CASES OF INFECTIOUS DISEASES 73
- 5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 74
- 5.2 RESTRAINTS 75
- 5.2.1 HIGH COST OF PCR TEST SERVICES 75
- 5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 76
- 5.3 OPPORTUNITIES 77
- 5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 77
- 5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 77
- 5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 78
- 5.4 CHALLENGES 79
- 5.4.1 DATA SECURITY AND PRIVACY CONCERNS 79
- 5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 79
6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 81
- 6.1 OVERVIEW 82
- 6.2 TUBERCULOSIS PCR TEST 88
- 6.3 HEPATITIS PCR TEST 88
- 6.3.1 HEPATITIS C PCR TEST 89
- 6.3.2 HEPATITIS B PCR TEST 89
- 6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 90
- 6.5 INFLUENZA PCR TEST 90
- 6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 91
- 6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 91
- 6.8 GONORRHEA PCR TEST 92
- 6.9 SALMONELLOSIS PCR TEST 92
- 6.10 ROTAVIRUS PCR TEST 93
- 6.11 BORDETELLA PCR TEST 93
- 6.12 H. PYLORI PCR TEST 94
- 6.13 SARS (COVID-19) PCR TEST 94
- 6.14 NOROVIRUS PCR TEST 95
- 6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 95
- 6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 96
- 6.17 ENTEROCOCCUS PCR TEST 96
- 6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 97
- 6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 97
- 6.20 OTHERS PCR TEST 98
7 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 99
- 7.1 OVERVIEW 100
- 7.2 VIRAL INFECTION 103
- 7.2.1 SARS (COVID-19) INFECTION 103
- 7.2.2 ROTAVIRUS INFECTION 103
- 7.2.3 NOROVIRUS INFECTION 103
- 7.2.4 OTHERS 104
- 7.3 RESPIRATORY TRACT INFECTION 104
- 7.3.1 INFLUENZA 104
- 7.3.2 TUBERCULOSIS 104
- 7.3.3 BORDETELLA 105
- 7.4 SEXUALLY TRANSMITTED INFECTION 105
- 7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 106
- 7.4.2 GONORRHEA 106
- 7.4.3 HEAPTITIS 106
- 7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 106
- 7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 106
- 7.4.6 MYCOPLASMA GENITALIUM (MG) 106
- 7.4.7 OTHERS 106
- 7.5 HOSPITAL ACQUIRED INFECTIONS 107
- 7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 107
- 7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 107
- 7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 108
- 7.5.4 OTHERS 108
- 7.6 OTHER INFECTIONS 108
- 7.6.1 SALMONELLOSIS 108
- 7.6.2 H. PYLORI 109
- 7.6.3 ENTEROCOCCUS INFECTIONS 109
- 7.6.4 OTHERS 109
8 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 110
- 8.1 OVERVIEW 111
- 8.2 VIRAL 114
- 8.3 BACTERIAL 114
- 8.4 FUNGAL 115
- 8.5 PROTOZOA 115
- 8.6 OTHERS 116
9 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 117
- 9.1 OVERVIEW 118
- 9.2 RT PCR 121
- 9.3 MULTIPLEX PCR 121
- 9.4 OTHERS 122
10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 123
- 10.1 OVERVIEW 124
- 10.2 GERIATRIC 127
- 10.3 PEDIATRIC 127
- 10.4 ADULTS 128
11 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 129
- 11.1 OVERVIEW 130
- 11.2 LABORATORY BASED TESTING 133
- 11.3 POINT OF CARE TESTING 133
12 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 134
- 12.1 OVERVIEW 135
- 12.2 DIAGNOSTIC CENTERS 138
- 12.3 HOSPITAL 138
- 12.4 CLINICS 139
- 12.5 COMMUNITY HEALTH CENTERS 139
- 12.6 ACADEMIC AND RESEARCH INSTITUTES 140
- 12.7 HOME HEALTHCARE 140
- 12.8 OTHERS 141
13 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 142
- 13.1 OVERVIEW 143
- 13.2 NORTH AMERICA 147
- 13.2.1 U.S. 156
- 13.2.2 CANADA 164
- 13.2.3 MEXICO 172
- 13.3 EUROPE 180
- 13.3.1 GERMANY 189
- 13.3.2 FRANCE 197
- 13.3.3 U.K. 205
- 13.3.4 ITALY 213
- 13.3.5 RUSSIA 221
- 13.3.6 SPAIN 229
- 13.3.7 TURKEY 237
- 13.3.8 NETHERLANDS 245
- 13.3.9 SWITZERLAND 253
- 13.3.10 BELGIUM 261
- 13.3.11 HUNGARY 269
- 13.3.12 REST OF EUROPE 277
- 13.4 ASIA PACIFIC 280
- 13.4.1 CHINA 290
- 13.4.2 AUSTRALIA 298
- 13.4.3 JAPAN 306
- 13.4.4 INDIA 314
- 13.4.5 SOUTH KOREA 322
- 13.4.6 SINGAPORE 330
- 13.4.7 MALAYISA 338
- 13.4.8 THAILAND 346
- 13.4.9 INDONESIA 354
- 13.4.10 PHILIPPINES 362
- 13.4.11 REST OF ASIA-PACIFIC 370
- 13.5 SOUTH AMERICA 373
- 13.5.1 BRAZIL 382
- 13.5.2 ARGENTINA 390
- 13.5.3 REST OF SOUTH AMERICA 398
- 13.6 MIDDLE EAST AND AFRICA 401
- 13.6.1 SOUTH AFRICA 410
- 13.6.2 U.A.E. 418
- 13.6.3 SAUDI ARABIA 426
- 13.6.4 EGYPT 434
- 13.6.5 ISRAEL 442
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 450
14 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 453
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 453
15 SWOT ANALYSIS 454
16 COMPANY PROFILE 455
- 16.1 MICROGEN DIAGNOSTICS 455
- 16.1.1 COMPANY SNAPSHOT 455
- 16.1.2 SERVICE PORTFOLIO 455
- 16.1.3 RECENT DEVELOPMENTS 456
- 16.2 MAX LAB 457
- 16.2.1 COMPANY SNAPSHOT 457
- 16.2.2 SERVICE PORTFOLIO 457
- 16.3 DNA LABS INDIA 459
- 16.3.1 COMPANY SNAPSHOT 459
- 16.3.2 SERVICE PORTFOLIO 459
- 16.3.3 RECENT DEVELOPMENT 460
- 16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD. 461
- 16.4.1 COMPANY SNAPSHOT 461
- 16.4.2 SERVICE PORTFOLIO 461
- 16.4.3 RECENT DEVELOPMENT 462
- 16.5 LALPATHLABS 463
- 16.5.1 COMPANY SNAPSHOT 463
- 16.5.2 REVENUE ANALYSIS 463
- 16.5.3 PRODUCT PORTFOLIO 464
- 16.5.4 RECENT DEVELOPMENTS 464
- 16.6 AZOVA 465
- 16.6.1 COMPANY SNAPSHOT 465
- 16.6.2 PRODUCT PORTFOLIO 465
- 16.6.3 RECENT DEVELOPMENTS 465
- 16.7 CLAREWELL CLINICS 466
- 16.7.1 COMPANY SNAPSHOT 466
- 16.7.2 PRODUCT DESCRIPTION 466
- 16.7.3 RECENT DEVELOPMENTS 466
- 16.8 DRSAFEHANDS 467
- 16.8.1 COMPANY SNAPSHOT 467
- 16.8.2 SERVICE PORTFOLIO 467
- 16.8.3 RECENT DEVELOPMENT 467
- 16.9 ONE LIFE HOME HEALTH CARE CENTER 468
- 16.9.1 COMPANY SNAPSHOT 468
- 16.9.2 PRODUCT DESCRIPTION 468
- 16.9.3 RECENT DEVELOPMENTS 468
- 16.10 PATHLAB 469
- 16.10.1 COMPANY SNAPSHOT 469
- 16.10.2 SERVICE PORTFOLIO 469
- 16.10.3 RECENT DEVELOPMENT 469
- 16.11 THE WASHINGTON TRAVEL CLINIC 470
- 16.11.1 COMPANY SNAPSHOT 470
- 16.11.2 SERVICE PORTFOLIO 470
- 16.11.3 RECENT DEVELOPMENT 471
17 QUESTIONNAIRE 472
18 RELATED REPORTS 476